<DOC>
	<DOCNO>NCT00927732</DOCNO>
	<brief_summary>The specific aim study determine whether hydroquinidine administration prevent heart appearance ventricular arrhythmia detect automatic implantable defibrillator ( ICD ) .</brief_summary>
	<brief_title>Hydroquinidine Versus Placebo Patients With Brugada Syndrome</brief_title>
	<detailed_description>During double-blind randomize cross-over study , patient receive 18 month treatment 1 ( hydroquinidine placebo ) , 7 day wash-out , patient receive treatment 2 ( mean example hydroquinidine treatment 1 placebo ) . Time length arisen appropriate shock register defibrillator ( mean due ventricular arrhythmia ) assess treatment 1 period treatment 2 period.We hypothesize hydroquinidine administration enhance time length arisen appropriate shock thus mean hydroquinidine administration prevent heart appearance ventricular arrhythmia . Patient 's defibrillator recording analyse every 6 month plus patient experience ICD shock . If shock deliver ICD appropriate happens treatment 1 period , patient switch treatment 2 period 7 day wash-out . If shock deliver ICD appropriate happens treatment 2 period , study finish patient.Before start study , patient test dose hydroquinidine she/he require hydroquinidine concentration her/his blood include 3 6 µmol/L . Planned enrollment : 200 subject ( 60 symptomatic history abort sudden cardiac death ventricular fibrillation , 70 symptomatic history syncope consider arrhythmic origin , 70 asymptomatic spontaneous type 1 ECG positive electrophysiological exploration )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Brugada Syndrome</mesh_term>
	<mesh_term>Hydroquinidine</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<criteria>Healthy adult ( least 18 year age ) Informed consent form sign Subject affiliate French health insurance ( Sécurité Sociale ) Type 1 Brugada syndrome either symptomatic asymptomatic Not pregnant , take oral contraceptive measure able procreate If patient asymptomatic type 1 Brugada , electrophysiological exploration must positive study inclusion No current intake `` betablocking '' medicine use cardiac insufficiency ( bisoprolol , carvedilol , metoprolol ) No current myasthenia No current treatment halofantrine , pentamidine , moxifloxacin No current treatment neuroleptic Known hypersensitivity hydroquinidine Intolerance fructose , syndrome glucose galactose malabsorption , deficit sucrase isomaltase Cardiac insufficiency Histories `` torsades de pointe '' Intake medicine give `` torsades de pointe '' Subject fulfil inclusion criterion Subject study entry hydroquinidine treatment either dose &gt; 3 capsule per day dose 1 , 2 3 capsule per day plasmatic hydroquinidine concentration &gt; 6µmol/L &lt; 3 µmol/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Brugada</keyword>
	<keyword>hydroquinidine</keyword>
	<keyword>ventricular arrhythmia</keyword>
	<keyword>patient Brugada syndrome , high cardiac arrhythmic risk implant implantable cardioverter defibrillator</keyword>
</DOC>